Detalhe da pesquisa
1.
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Ann Oncol
; 34(12): 1141-1151, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072514
2.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Ann Oncol
; 34(10): 885-898, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597578
3.
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Ann Oncol
; 32(4): 488-499, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33385521
4.
Epigenetic regulation and nucleosome positioning in the human TATA-less IL-1 alpha promoter.
Genes Immun
; 9(7): 582-90, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18615092
5.
Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.
Cell Death Differ
; 18(2): 271-81, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20689556